Research: ZHORNITSKY and COLLEAGUES,

Listed in Issue 235

Abstract

ZHORNITSKY and COLLEAGUES,  (1)Multiple Sclerosis Program, Department of Clinical Neurosciences, University of Calgary, Canada conducted a systematic review to examine the known associations between prolactin (PRL) and MS to elucidate its potential role in the pathophysiology and treatment of MS.

Background

Multiple sclerosis (MS) is more common among women than men. MS often goes into remission during pregnancy, when prolactin (PRL) levels are known to be high. In an animal model of demyelination, PRL promoted myelin repair, suggesting it has potential as a remyelinating therapy in MS.

Methodology

In this systematic review, we examined the known associations between PRL and MS, in order to elucidate its potential role in the pathophysiology and treatment of MS. A systematic search was performed in the electronic databases PubMed and EMBASE, using the keywords "prolactin" AND "multiple sclerosis." The inclusion criteria were met by 23 studies.

Results

These studies suggested to us that elevated PRL may be more common in MS patients than in controls. Hyperprolactinemia may also be associated with clinical relapse in MS, especially among patients with hypothalamic lesions or optic neuritis; however, it is unknown if this is a cause or consequence of a relapse. Overall, most people with MS have normal PRL levels. The impact of PRL on MS outcomes remains unclear.

Conclusion

References

Zhornitsky S(1), Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler. 19(1):15-23. Jan 2013. doi: 10.1177/1352458512458555. Epub Aug 29 2012.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page